Spartin (SPART) (Internal Region) antibody
Quick Overview for Spartin (SPART) (Internal Region) antibody (ABIN570717)
Target
Reactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Binding Specificity
- Internal Region
-
Purpose
- SPARTIN
-
Sequence
- EASGTDVKQL DQGNK
-
Cross-Reactivity
- Human
-
Purification
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
-
Immunogen
- Peptide with sequence C-EASGTDVKQLDQGNK, from the internal region of the protein sequence according to NP_055902.1.
-
Isotype
- IgG
-
-
-
-
Application Notes
-
Western Blot: Approx 70 kDa band observed in lysates of cell line HeLa (calculated MW of 72.8 kDa according to NP_055902.1). Recommended concentration: 1-3 μg/mL.
Peptide ELISA: antibody detection limit dilution 1:8000.
-
Comment
-
Immunofluorescence: HeLa show dimished signals after knock down of expresssion by introduction of siRNA.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.5 mg/mL
-
Buffer
- Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Minimize freezing and thawing.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.
-
-
- Spartin (SPART)
-
Alternative Name
- SPART
-
Background
- SPG20, spastic paraplegia 20 (Troyer syndrome), KIAA0610, SPARTIN, TAHCCP1, OTTHUMP00000018254, spastic paraplegia 20, spastic paraplegia 20, spartin (Troyer syndrome), trans-activated by hepatitis C virus core protein 1
-
Gene ID
- 23111
-
NCBI Accession
- NP_055902
Target
-